Inclusion Criteria:

- Cutaneous sclerosis after hematopoietic cell transplant (HCT) diagnosed no more than
18 months before study enrollment with sclerotic skin, morphea, myofascial
involvement or joint contractures with a score of 2 or greater on the Vienna skin
scale in any area, or a score of 5 or less at the shoulder, elbow or wrist, or a
score of 3 or less at the ankle on the range-of-motion (ROM) assessment

- Stable doses of systemic immunosuppressive medications for a minimum of 4 weeks prior
to the date of consent

- Receiving corticosteroids at a dose greater than required for treatment of adrenal
insufficiency, unless the physician documents why steroids are contraindicated

- Age 2-99 years

- Karnofsky performance status >= 60% at enrollment

- All females of childbearing potential must have a negative serum or urine pregnancy
test =< 7 days prior to starting study therapy

- All females of childbearing potential must agree to use a form of Food and Drug
Administration (FDA) approved contraception from enrollment to one month after study
treatment ends

- Subject has the ability to understand and willingness to sign a written informed
consent document

Exclusion Criteria:

- Total bilirubin > 1.5x upper limit of normal (ULN)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN

- Renal insufficiency (serum creatinine > 2.0 mg/dl)

- Platelets < 30,000/ul or absolute neutrophil count < 1500/ul

- Known hypersensitivity to Rituximab or other anti-B cell antibodies

- Known Imatinib intolerance or allergy

- Evidence of any active viral, bacterial, or fungal infection that is progressive
despite appropriate treatment

- Known hepatitis B surface antigen positive

- Pregnant, lactating, or planning a pregnancy while in the study

- Distal extremity skin score 3 or higher as the only manifestation of sclerosis

- Treatment of chronic GVHD with either Imatinib or Rituximab, or receipt of Imatinib
or Rituximab within the previous 6 months for any other indication

- History of psychiatric disorder that would interfere with normal participation in
this study

- Inability or unwillingness of subject and/or parent guardian to provide informed
consent or comply with study protocol

- Use of non-FDA approved drugs within 4 weeks of participation

- Patient with any condition that, in the opinion of the investigator, would interfere
with the subject's ability to comply with the study requirements

- Patients with uncontrolled substance abuse

- Current treatment with sirolimus (patients may stop sirolimus on the day of
enrollment; if randomized to imatinib, they should wait seven days before starting
the study drug)